Haemangioblastoma of the central nervous system in von Hippel-Lindau disease

Journal of Internal Medicine

Volumn 243, Issue 6, 1998, Pages 547-553

  Richard, S ^a   Campello, C ^b   Taillandier, L ^c   Parker, F ^d   Resche, F ^e,f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b DEPARTMENT OF NEUROLOGY   (France)

^c Hopital Saint Julien Nancy   (France)

^d BICÊTRE HOSPITAL   (France)

^e CHU de Nantes   (France)

^f French VHL Study Group

Author keywords

Haemangioblastoma; Nervous system; Von Hippel Lindau disease

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR;

CELL DIFFERENTIATION; CONFERENCE PAPER; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; GENE MUTATION; HEMANGIOBLASTOMA; HUMAN; INTRACRANIAL PRESSURE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TUMOR LOCALIZATION; VON HIPPEL LINDAU DISEASE;

EID: 0031837459     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00337.x     Document Type: Conference Paper

References (28)

1. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989; 68: 1-29.
2. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-Smith MA. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990; 77: 1151-6.
3. Resche F, Moisan JP, Mantoura J, de Kersaint-Gilly A, André MJ. Perrin-Resche I et al. Haemangioblastomas. haemangioblastomatosis and von Hippel-Lindau disease. Adv Techn Stand Neurosurg 1943; 20: 197-303.
4. Richard S, Chauveau D, Chrétien Y, Beigelman C, Denys A, Fendler JP et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol 1994; 23: 1-27.
5. Neumann HPH, Lips CJM. Hsia YE, Zbar B, von Hippel-Lindau syndrome. Brain Pathol 1995; 5: 181-93.
6. Maddock IR. Moran A, Maher ER, Teare MD, Norman A, Payne SJ et al. A genetic register for von Hippel-Lindau disease. J Med Genet 1996; 33: 120-27.
7. Filling-Katz MR, Choyke PL, Oldfield E, Charnas L, Patronas NJ, Glenn GM et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology 1991; 41: 41-6.
8. Neumann HPH, Eggert HR, Scheremet R, Schumacher M. Mohadjer M, Wakhloo AK et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatr 1992; 55: 898-901.
9. Linehan WM, Lerman MI. Zbar B Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J Am Med Ass 1995; 273: 564-70.
10. Zbar B, Kishida T, Chen F, Schmidt L, Lerman MI, Maher E et al. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe and Japan. Hum Mutat 1996; 8: 348-57.
11. Boughey AM, Fletcher NA, Harding AE. Central nervous system haemangioblastoma: a clinical and genetic study of 52 cases. J Neurol Neurosurg Psychiatr 1990; 53: 644-8.
12. Richard S, Beigelman C, Gerber S, Van Effenterre R. Gaudric A. Sahel M et al. L'hémangioblastome existe-t-il en dehors de la maladie de von Hippel-Lindau? Neurochirurdie 1994; 40: 145-54.
13. Neumann HPH, Eggert HR, Weigel K, Freidburg H, Wiestler OD. Schollmeyer P. Haemangioblastoma of the central nervous system: a ten-year study with special reference to von Hippel-Lindau syndrome. J Neurosurg 1989; 70: 23-30.
14. Maher ER, Yates JRW, Ferguson-Smith MA. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 1990; 27: 311-4.
15. Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. J Am Med Assoc 1997; 277: 1461-6.
16. Niemelä M, Lim YJ, Söderman M, Jääskelainäinen J, Lindquist C. Gamma knife radiosurgery in 11 haemangioblastoma. J Neurosurg 1996; 85: 591-6.
17. Decker HJH, Weidt EJ, Brieger J. The von Hippel-Lindau tumour suppressor gene. Cancer Genet Cytogenet 1997; 93: 74-83.
18. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe T et al. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system Haemangioblastoma. Cancer Res 1994; 54: 4845-7.
19. Oberstrass J, Reifenberger G, Wechsler W, Collins VP. Mutation of the von Hippel-Lindau tumour suppressor gene in capillary haemangioblastormas of the central nervous system. J Pathol 1996; 179: 151-6.
20. Tse JYM, Wong JHC, Lo KW, Poon WS, Huang DP, Ng HK, Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar haemangioblastomas. Am J Clin Pathol 1997; 107: 459-66.
21. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997; 60: 765-71.
22. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfiekd EH, Zhuang Z, von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar haemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997; 28: 540-43.
23. Wizigmann-Voos S, Breiuer G, Risau W, Plate KH. Upregulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic haemangioblastoma. Cancer Res 1995; 55: 1358-64.
24. Hatva E, Böhling T, Jääskeläinen J, Persico MG, Haltia M, Alitalo K, Vascular growth factors and receptors in capillary haemangioblastomas and haemangiopericytomas. Am J Pathol 1996; 148: 763-75.
25. Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995; 269: 1402-6.
26. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci 1996; 93: 10595-9.
27. Levy AP, Levy NS, Goldberg MA. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA ant its modulation by the von Hippel-Lindau protein. J Biom Chem 1996; 271: 25492-7.
28. Gnarra JR. Zhou S. Merrill MJ, Wagner JR, Krumm A, Papavassiliou E et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1995; 93: 10589-94.